Trial Outcomes & Findings for Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML (NCT NCT03306264)

Last Updated: 2024-08-27

Results Overview

Total 5-day ASTX727 AUC0-24 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-24 (first ASTX727 dose) was added to (Day 2 AUC0-24+ Day 5 AUC0-24) × 2. Decitabine 5-day AUC0-24 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-24+ Day 5 AUC0-24) / 2 was multiplied by 5. If AUC0-24 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-24 on Day 5; the converse was also true.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

227 participants

Primary outcome timeframe

ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

Results posted on

2024-08-27

Participant Flow

A total of 227 participants took part in the study from 15 February 2018 to 25 May 2023. 138 participants with a diagnosis of myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) took part from the United States and Canada. 89 participants with a diagnosis of acute myeloid leukemia (AML) took part from Austria, Canada, Czech Republic, France, Germany, Hungary, Italy, Spain, and United Kingdom.

A total of 138 participants with a diagnosis of MDS or CMML were enrolled and randomized in a 1:1 ratio to receive ASTX727 or decitabine in a crossover manner. A total of 89 participants with a diagnosis of AML were enrolled and randomized in a 1:1 ratio to receive ASTX727 or decitabine in a crossover manner.

Participant milestones

Participant milestones
Measure	MDS or CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	MDS or CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.	AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Overall Study STARTED	69	69	44	45
Overall Study Safety Analysis Set	66	67	43	44
Overall Study COMPLETED	0	0	0	0
Overall Study NOT COMPLETED	69	69	44	45

Reasons for withdrawal

Reasons for withdrawal
Measure	MDS or CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	MDS or CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.	AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727 Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Overall Study Death	33	25	34	34
Overall Study Complete Consent Withdrawal	4	4	1	8
Overall Study Lost to Follow-up	1	0	1	0
Overall Study Rollover to ASTX727-06	10	18	4	2
Overall Study Study Centre Terminated by Sponsor	21	22	4	1

Baseline Characteristics

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	MDS or CMML: ASTX727 or IV Decitabine n=133 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2 or the converse. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: ASTX727 or IV Decitabine n=87 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycle 2 or the converse. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.	Total n=220 Participants Total of all reporting groups
Age, Customized 18 to 64 years	36 Participants n=5 Participants	3 Participants n=7 Participants	39 Participants n=5 Participants
Age, Customized 65 to 84 years	93 Participants n=5 Participants	75 Participants n=7 Participants	168 Participants n=5 Participants
Age, Customized ≥85 years	4 Participants n=5 Participants	9 Participants n=7 Participants	13 Participants n=5 Participants
Sex: Female, Male Female	46 Participants n=5 Participants	34 Participants n=7 Participants	80 Participants n=5 Participants
Sex: Female, Male Male	87 Participants n=5 Participants	53 Participants n=7 Participants	140 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	6 Participants n=5 Participants	0 Participants n=7 Participants	6 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	125 Participants n=5 Participants	0 Participants n=7 Participants	125 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants n=5 Participants	87 Participants n=7 Participants	89 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	3 Participants n=5 Participants	0 Participants n=7 Participants	3 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	4 Participants n=5 Participants	0 Participants n=7 Participants	4 Participants n=5 Participants
Race (NIH/OMB) White	121 Participants n=5 Participants	0 Participants n=7 Participants	121 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	5 Participants n=5 Participants	87 Participants n=7 Participants	92 Participants n=5 Participants

PRIMARY outcome

Timeframe: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

Population: Primary Endpoint Pharmacokinetics (PK) Analysis Set included participants who received full dose of ASTX727 within 3 hours of the intended dosing time, and no vomiting within 6 hours of dosing, and had at least 2 days of evaluable decitabine (AUC0-24) measurements in the ASTX727 cycle, i.e, Day 1 and either Day 2 or Day 5 and received the full IV decitabine dose as a 1-hour infusion.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=123 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=123 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=69 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=69 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine	864.34 hoursnanograms per milliliter (hng/mL) Geometric Coefficient of Variation 40.0	855.96 hoursnanograms per milliliter (hng/mL) Geometric Coefficient of Variation 50.6	910.1 hoursnanograms per milliliter (hng/mL) Geometric Coefficient of Variation 52.4	900.5 hoursnanograms per milliliter (hng/mL) Geometric Coefficient of Variation 52.0

SECONDARY outcome

Timeframe: From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)

Population: The Safety Analysis Set included all participants who received any amount of study treatment.

An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=132 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=130 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	127 Participants	130 Participants	—	—

SECONDARY outcome

Timeframe: From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)

Population: The Safety Analysis Set included all participants who received any amount of study treatment.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=78 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=80 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Number of Participants With Treatment-emergent Adverse Events (AEs)	71 Participants	80 Participants	—	—

SECONDARY outcome

Timeframe: From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)

Population: The Safety Analysis Set included all participants who received any amount of study treatment.

TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=132 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=130 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs	89 Participants	121 Participants	—	—

SECONDARY outcome

Timeframe: From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)

Population: The Safety Analysis Set included all participants who received any amount of study treatment.

TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using CTCAE version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=78 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=80 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Number of Participants With Grade 3 or Higher TEAEs	43 Participants	73 Participants	—	—

SECONDARY outcome

Timeframe: Pre-dose on Day 1 of Cycles 1 and 2 (as Baseline), and Days 8, 15 and 22 of Cycles 1 and 2 (each cycle= 28 days)

Population: Pharmacodynamic (PD) LINE-1 Analysis Set included participants who received any amount of study treatment and have LINE-1 methylation data at baseline (Day 1) of Cycle 1 or 2 and on either Day 8 or Day 15 of the respective cycle. 'Overall number of participants analyzed' signifies those who were evaluable for this outcome measure. 'Number analyzed' signifies those participants who were evaluable for this outcome measure at specified time point.

Summarized data for Cycle 1 and Cycle 2 was reported.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=63 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=63 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=39 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=34 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Maximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation Cycle 2	11.968 percentage of demethylation Interval 10.503 to 13.434	11.151 percentage of demethylation Interval 9.685 to 12.616	8.153 percentage of demethylation Interval 6.226 to 10.079	8.037 percentage of demethylation Interval 6.258 to 9.816
Maximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation Cycle 1	14.019 percentage of demethylation Interval 12.528 to 15.51	13.289 percentage of demethylation Interval 11.798 to 14.78	8.243 percentage of demethylation Interval 6.34 to 10.147	9.357 percentage of demethylation Interval 7.288 to 11.426

SECONDARY outcome

Population: Overall PK Analysis Set included participants who may not have been included in the Primary Endpoint PK Analysis Set and who received any amount of study treatment, complied with the protocol sufficiently to ensure PK samples were collected as intended and provided sufficient samples to measure available plasma concentrations for decitabine. 'Overall number of participants analyzed' signifies those who were evaluable for this outcome measure.

Total 5-day ASTX727 AUC0-inf exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-inf (first ASTX727 dose) was added to (Day 2 AUC0-inf+ Day 5 AUC0-inf) × 2. Decitabine 5-day AUC0-inf exposures after IV decitabine were calculated as follows: (Day 1 AUC0-inf+ Day 5 AUC0-inf) / 2 was multiplied by 5. If AUC0-inf on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-inf on Day 5; the converse was also true.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=123 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=123 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=69 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=69 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Total 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine	866.15 h*ng/mL Geometric Coefficient of Variation 39.9	849.63 h*ng/mL Geometric Coefficient of Variation 50.4	912.3 h*ng/mL Geometric Coefficient of Variation 52.3	902.1 h*ng/mL Geometric Coefficient of Variation 51.8

SECONDARY outcome

Population: Overall PK Analysis Set included participants who may not have been included in the Primary Endpoint PK Analysis Set and received any amount of study treatment, complied with the protocol sufficiently to ensure PK samples were collected as intended and provided sufficient samples to measure available plasma concentrations for decitabine. 'Overall number of participants analyzed' signifies those who were evaluable for this outcome measure.

Total 5-day ASTX727 AUC0-last exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-last (first ASTX727 dose) was added to (Day 2 AUC0-last + Day 5 AUC0-last) × 2. Decitabine 5-day AUC0-last exposures after IV decitabine were calculated as follows: (Day 1 AUC0-last + Day 5 AUC0-last) / 2 was multiplied by 5. If AUC0-last on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-last on Day 5; the converse was also true.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=124 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=124 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=70 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=70 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Total 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine	853.02 h*ng/mL Geometric Coefficient of Variation 40.7	837.38 h*ng/mL Geometric Coefficient of Variation 50.7	902.7 h*ng/mL Geometric Coefficient of Variation 53.0	881.8 h*ng/mL Geometric Coefficient of Variation 52.5

SECONDARY outcome

Timeframe: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

Total 5-day ASTX727 AUC0-8 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-8 (first ASTX727 dose) was added to (Day 2 AUC0-8 + Day 5 AUC0-8) × 2. Decitabine 5-day AUC0-8 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-8 + Day 5 AUC0-8) / 2 was multiplied by 5. If AUC0-8 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-8 on Day 5; the converse was also true.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=124 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=124 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=70 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=70 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Total 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine	856.63 h*ng/mL Geometric Coefficient of Variation 40.6	839.37 h*ng/mL Geometric Coefficient of Variation 50.4	910.1 h*ng/mL Geometric Coefficient of Variation 52.0	883.8 h*ng/mL Geometric Coefficient of Variation 52.1

SECONDARY outcome

Timeframe: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)

Population: Overall PK Analysis Set included participants not included in Primary Endpoint PK Analysis Set, received any amount of study treatment, complied with protocol sufficiently to ensure PK samples were collected, provided sufficient samples to measure available plasma concentrations for decitabine. Overall number of participants analyzed:Number of participants evaluable for this outcome measure. Number analyzed:Number of participants evaluable for this outcome measure at specified time point.

AUC0-inf was calculated using the formula AUClast + (Clast / λZ), where Clast is the last quantifiable concentration and λZ is the elimination rate constant. AUC0-inf will be calculated using the linear up-log down method. Summarized data has been reported for cycle 1 and 2.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=119 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=127 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=70 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=78 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine Day 1	174 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 40.8	102 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 54.8	175 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 54.9	118 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 54.4
Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine Day 2	—	186 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 55.3	—	193 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 59.6
Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine Day 5	170 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 41.7	178 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 52.7	181 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 58.1	187 nanogramshours per millilitres(ngh/mL) Geometric Coefficient of Variation 57.1

SECONDARY outcome

Summarized data of Cmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Cmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=122 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=128 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=72 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=79 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 5	—	169 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 65.9	—	191 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 58.4
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 1	184 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 48.1	83.1 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 66.1	187 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 64.7	85.9 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 56.6
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 2	—	145 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 54.7	—	139 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 58.5
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 5	180 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 49.2	140 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 62.8	192 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 62.4	139 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 62.7
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 1	—	321 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 53.8	—	313 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 47.7
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 2	—	349 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 49.1	—	343 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 43.4
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 5	—	371 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 51.8	—	350 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 42.7
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 1	—	150 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 65.7	—	182 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 60.0
Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 2	—	155 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 64.6	—	204 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 59.2

SECONDARY outcome

Summarized data of Tmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Tmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=122 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=128 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=72 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=79 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 5	—	3.00 hours Interval 1.5 to 6.12	—	3.98 hours Interval 1.0 to 8.0
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 1	—	3.08 hours Interval 1.5 to 7.97	—	4.00 hours Interval 1.5 to 8.03
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 1	0.98 hours Interval 0.23 to 1.27	1.00 hours Interval 0.48 to 3.0	0.98 hours Interval 0.25 to 2.0	1.00 hours Interval 0.25 to 2.02
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 2	—	1.00 hours Interval 0.47 to 2.0	—	1.00 hours Interval 0.25 to 3.0
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 5	0.97 hours Interval 0.25 to 1.62	1.00 hours Interval 0.25 to 3.0	0.98 hours Interval 0.0 to 1.17	1.00 hours Interval 0.47 to 3.0
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 1	—	3.00 hours Interval 1.5 to 7.97	—	3.98 hours Interval 1.47 to 8.0
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 2	—	3.01 hours Interval 0.52 to 7.88	—	4.00 hours Interval 1.0 to 7.88
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 2	—	3.03 hours Interval 0.52 to 7.88	—	4.00 hours Interval 1.5 to 7.88
Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 5	—	3.08 hours Interval 1.0 to 8.05	—	4.00 hours Interval 1.53 to 8.0

SECONDARY outcome

Timeframe: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)

Oral CL/F for oral decitabine was measured only on Day 1 and oral CL/F for oral cedazuridine was measured on Days 1, 2 and 5. Summarized data of Oral CL/F for oral decitabine on Day 1 for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of oral CL/F for oral cedazuridine on Day 1,2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=127 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=78 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine Cedazuridine: Day 2	25.6 Litres per hour (L/h) Geometric Coefficient of Variation 159	27.4 Litres per hour (L/h) Geometric Coefficient of Variation 45.4	—	—
Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine Decitabine: Day 1	342 Litres per hour (L/h) Geometric Coefficient of Variation 54.8	297 Litres per hour (L/h) Geometric Coefficient of Variation 54.4	—	—
Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine Cedazuridine: Day 1	30.6 Litres per hour (L/h) Geometric Coefficient of Variation 46.4	28.6 Litres per hour (L/h) Geometric Coefficient of Variation 55.5	—	—
Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine Cedazuridine: Day 5	16.8 Litres per hour (L/h) Geometric Coefficient of Variation 15.9	86.8 Litres per hour (L/h) Geometric Coefficient of Variation NA Geometric Coefficient of Variation could not be calculated as data for only one participant was available for analysis.	—	—

SECONDARY outcome

Summarized data of t1/2 on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of t1/2 on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=119 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=127 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=70 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=78 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 1	0.967 hours Geometric Coefficient of Variation 46.8	1.18 hours Geometric Coefficient of Variation 22.8	1.16 hours Geometric Coefficient of Variation 56.7	1.07 hours Geometric Coefficient of Variation 31.6
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 5	—	2.59 hours Geometric Coefficient of Variation 5.43	—	2.41 hours Geometric Coefficient of Variation NA Geometric Coefficient of Variation could not be calculated as data for only one participant was available for analysis.
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 1	—	5.50 hours Geometric Coefficient of Variation 21.8	—	6.22 hours Geometric Coefficient of Variation 17.4
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 2	—	1.38 hours Geometric Coefficient of Variation 24.7	—	1.36 hours Geometric Coefficient of Variation 35.0
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Decitabine: Day 5	1.14 hours Geometric Coefficient of Variation 44.9	1.47 hours Geometric Coefficient of Variation 26.9	1.18 hours Geometric Coefficient of Variation 49.0	1.45 hours Geometric Coefficient of Variation 34.0
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 1	—	6.33 hours Geometric Coefficient of Variation 18.1	—	6.68 hours Geometric Coefficient of Variation 18.5
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine: Day 2	—	6.70 hours Geometric Coefficient of Variation 18.9	—	7.05 hours Geometric Coefficient of Variation 17.6
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 2	—	5.90 hours Geometric Coefficient of Variation 23.2	—	6.15 hours Geometric Coefficient of Variation 22.8
Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer Cedazuridine-epimer: Day 5	—	2.58 hours Geometric Coefficient of Variation 5.16	—	2.57 hours Geometric Coefficient of Variation NA Geometric Coefficient of Variation could not be calculated as data for only one participant was available for analysis.

SECONDARY outcome

Timeframe: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)

Summarized data of Vz/F on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=127 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=78 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine Decitabine: Day 5	417 Litres Geometric Coefficient of Variation 54.3	373 Litres Geometric Coefficient of Variation 68.9	—	—
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine Cedazuridine: Day 1	280 Litres Geometric Coefficient of Variation 50.9	272 Litres Geometric Coefficient of Variation 59.9	—	—
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine Decitabine: Day 1	585 Litres Geometric Coefficient of Variation 55.0	434 Litres Geometric Coefficient of Variation 60.4	—	—
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine Decitabine: Day 2	369 Litres Geometric Coefficient of Variation 59.0	337 Litres Geometric Coefficient of Variation 67.6	—	—
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine Cedazuridine: Day 2	296 Litres Geometric Coefficient of Variation 51.3	278 Litres Geometric Coefficient of Variation 49.8	—	—
Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine Cedazuridine: Day 5	62.8 Litres Geometric Coefficient of Variation 10.4	302 Litres Geometric Coefficient of Variation NA Geometric Coefficient of Variation could not be calculated as data for only one participant was available for analysis.	—	—

SECONDARY outcome

Timeframe: Up to approximately 2.7 years

Population: Efficacy Analysis Set included all participants who received any amount of study treatment.

CR: normal peripheral, persistent granulocyte count ≥1.0x10\^9/liter(L), platelet ≥100x10\^9/L, Hemoglobin (Hgb) ≥11g/dL, normal bone marrow with persistent marrow blasts ≤5%. mCR: reduction of bone marrow blasts to≤5%, decrease by 50% or more with/without normalization of peripheral counts.PR: normal peripheral counts, granulocyte count ≥1.0x10\^9/L, platelet count ≥100x10\^9/L, Hgb ≥11 g/dL, normal bone marrow, marrow blasts \>5%, reduced by 50% or more for at least 4 weeks. HI: HI-E: Hb increase ≥1.5 g/dL in absence of RBC transfusions. HI-P: Absolute increase of platelet count from \<20 to \>20X10\^9/L by at least 100%,if more than 20x10\^9/L, by absolute increase of at least 30x10\^9/L in absence of platelet transfusions. HI-N: granulocyte increase ≥100%, by an absolute increase ≥0.5x10\^9/L for at least 8 weeks. Percentage of participants with CR, mCR, PR, and HI based on IWG 2003 MDS response criteria are reported. Response has been reported based on participants with MDS or CMML.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=61 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=56 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine n=5 Participants Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 n=11 Participants Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria HI: Neutrophil Response (HI-N)	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0	9.1 percentage of participants Interval 0.2 to 41.3
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria Complete Response (CR)	26.2 percentage of participants Interval 15.8 to 39.1	19.6 percentage of participants Interval 10.2 to 32.4	0 percentage of participants Interval 0.0 to 0.0	18.2 percentage of participants Interval 2.3 to 51.8
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria Marrow Complete Response (mCR)	29.5 percentage of participants Interval 18.5 to 42.6	30.4 percentage of participants Interval 18.8 to 44.1	40.0 percentage of participants Interval 5.3 to 85.3	54.5 percentage of participants Interval 23.4 to 83.3
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria Partial Response (PR)	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria HI: Erythroid Response (HI-E)	0 percentage of participants Interval 0.0 to 0.0	1.8 percentage of participants Interval 0.0 to 9.6	20.0 percentage of participants Interval 0.5 to 71.6	0 percentage of participants Interval 0.0 to 0.0
MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria HI: Platelet Response (HI-P)	3.3 percentage of participants Interval 0.4 to 11.3	8.9 percentage of participants Interval 3.0 to 19.6	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Up to approximately 2.4 years

Population: Efficacy Analysis Set included all participants who received any amount of study treatment.

CR was defined as absolute neutrophil content (ANC) ≥1000/ microliter (μL), platelets ≥100,000/μL, independence from red blood cell (RBC) and platelet transfusions over the past week, no leukemic blasts and \<5% leukemic blasts. CRp was defined as CR criteria except platelets \<100,000/μL.and platelet transfusion over the past week. CRi was defined as CR criteria except ANC \<1000/μL or platelets \<100,000/μL. Percentage of participants with CR, CRi, CRp, and CR Plus CRp based on IWG 2003 AML response criteria are reported.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=43 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=44 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria Complete Response (CR)	14.0 percentage of participants Interval 5.3 to 27.9	29.5 percentage of participants Interval 16.8 to 45.2	—	—
AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria CR with Incomplete Platelet Recovery (CRp)	4.7 percentage of participants Interval 0.6 to 15.8	0 percentage of participants Interval 0.0 to 8.0	—	—
AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria CR with Incomplete Blood Count Recovery (CRi)	11.6 percentage of participants Interval 3.9 to 25.1	0 percentage of participants Interval 0.0 to 8.0	—	—
AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria CR Plus CRp	18.6 percentage of participants Interval 8.4 to 33.4	29.5 percentage of participants Interval 16.8 to 45.2	—	—

SECONDARY outcome

Timeframe: Day 1 of Cycle 3 up to approximately 2.4 years (each cycle= 28 days)

Population: Efficacy Analysis Set included all participants who received any amount of study treatment.

CRh was defined as \<5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets \>50,000/μL and ANC \>500/μL), independence from RBC and platelet transfusions within 7 days of bone marrow evaluation, and peripheral blast ≤1%. Percentage of participants with CRh based on IWG 2003 AML response criteria are reported.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=43 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 n=44 Participants Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria	4.7 percentage of participants Interval 0.6 to 15.8	0 percentage of participants Interval 0.0 to 8.0	—	—

SECONDARY outcome

Timeframe: Up to approximately 2.4 years

Population: Efficacy Analysis Set included all participants who received any amount of study treatment.

Time to first response was defined as time in months from the date of first treatment to the first date when any response is achieved. Time to best response was defined in months from the date of first treatment to the first date when a subject's best response, in the order of CR, CRi (or CRp or CRh), or PR, was achieved. Time to CR was defined in months from the date of first treatment to the first date when CR is achieved. CR:ANC ≥1000/ microliter (μL),platelets ≥100,000/μL,independence from RBC and platelet transfusions over the past week, no leukemic blasts, and \<5% leukemic blasts.CRp: CR criteria except ANC ≥1000/μL, platelets \< 100,000/μL.and platelet transfusion over the past week. CRi:CR criteria except ANC \<1000/μL or platelets \<100,000/μL.CRh: \<5% of blasts in the bone marrow,platelets \>50,000/μL and ANC \>500/μL, independence from RBC and platelet transfusions within 7 days and peripheral blast ≤1%. PR: CR criteria except decrease of ≥50% in leukemic blasts.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=87 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria Time to First Response	2.91 months Interval 1.9 to 6.5	—	—	—
AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria Time to Best Response	3.45 months Interval 1.9 to 7.5	—	—	—
AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria Time to Complete Response	3.02 months Interval 1.9 to 7.5	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 2.4 years

Population: Efficacy Analysis Set included all participants who received any amount of study treatment.

Duration of CR was defined as the time interval from the first CR to time of relapse. Duration of combined CR and CRh was defined as the time interval from the first CR or CRh to time of relapse. Duration of CR and combined CR and CRh was presented using a Kaplan-Meier estimate.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=87 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria Duration of Complete Response	6.9 months Interval 3.4 to 11.5	—	—	—
AML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria Duration of Combined CR and CRh	9.0 months Interval 3.4 to 11.5	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 2.7 years

Population: Efficacy Analysis Set included all participants who received any amount of study treatment. 'Overall number of participants analyzed' signifies those who were evaluable for this outcome measure. 'Number analyzed' signifies those subjects who were evaluable for this outcome measure in specified category.

Transfusion independence was defined as no transfusion for 56 consecutive days or more (84 and 112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=54 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) Platelet TI: ≥84 Days	33.3 percentage of participants Interval 9.9 to 65.1	—	—	—
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) RBC TI: ≥56 Days	51.9 percentage of participants Interval 37.8 to 65.7	—	—	—
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) RBC TI: ≥84 Days	40.7 percentage of participants Interval 27.6 to 55.0	—	—	—
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) RBC TI: ≥112 Days	33.3 percentage of participants Interval 21.1 to 47.5	—	—	—
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) Platelet TI: ≥56 Days	50.0 percentage of participants Interval 21.1 to 78.9	—	—	—
MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) Platelet TI: ≥112 Days	33.3 percentage of participants Interval 9.9 to 65.1	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 2.4 years

Transfusion independence was defined as no transfusion for 56 consecutive days or more (112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI).

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=37 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) RBC TI ≥56 Days	37.8 percentage of participants Interval 22.5 to 55.2	—	—	—
AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) RBC TI ≥112 Days	24.3 percentage of participants Interval 11.8 to 41.2	—	—	—
AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) Platelet TI ≥56 Days	35.7 percentage of participants Interval 12.8 to 64.9	—	—	—
AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI) Platelet TI ≥112 Days	28.6 percentage of participants Interval 8.4 to 58.1	—	—	—

SECONDARY outcome

Timeframe: From randomization up to approximately 2.7 years

LFS was defined as time from the date of randomization to the date when bone marrow or peripheral blood blasts reach ≥20%, or death from any cause. Participants who hadn't reached AML at the time of the analysis were censored at the date of the last follow-up. Leukemia-free survival was presented using a Kaplan-Meier estimate.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=62 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
MDS/CMML: Leukemia-free Survival (LFS)	889.0 days Interval 674.0 to The upper limit of the 95% Confidence Interval (CI) was not reached at time of data cut-off due to insufficient number of participants with an event.	—	—	—

SECONDARY outcome

Timeframe: From randomization up to approximately 2.7 years

OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=58 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
MDS/CMML: Overall Survival (OS)	966.0 days Interval 809.0 to The upper limit of the 95% CI was not reached at time of data cut-off due to insufficient number of participants with an event.	—	—	—

SECONDARY outcome

Timeframe: From randomization up to approximately 2.4 years

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=67 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Overall Survival (OS)	8.9 months Interval 5.9 to 13.1	—	—	—

SECONDARY outcome

Timeframe: At Month 6, Year 1 and 2

Population: Efficacy Analysis Set included all participants who received any amount of study treatment.

One-year survival rate was defined as the survival rate at the end of the first year from the date of randomization. The survival rates at 6 months and at 2 years were calculated similarly.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=87 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Survival Rates at 6 Months, 1 Year, and 2 Years Month 6	61 percentage of participants Interval 50.0 to 71.0	—	—	—
AML: Survival Rates at 6 Months, 1 Year, and 2 Years Year 1	44 percentage of participants Interval 33.0 to 54.0	—	—	—
AML: Survival Rates at 6 Months, 1 Year, and 2 Years Year 2	16 percentage of participants Interval 8.0 to 26.0	—	—	—

SECONDARY outcome

Timeframe: From randomization up to approximately 2.4 years

EFS was defined as time from the date of randomization to the date of treatment failure \[disease progression/relapse (due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse), discontinue treatment due to disease progression or treatment-related AE, or alternative anti-leukemia therapy except for HCT\] or death from any cause, whichever occurs first. Participants without documented treatment failure at the time of the analysis were censored at the date of the last follow-up. Event-free survival was presented using a Kaplan-Meier estimate.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=82 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Event-free Survival (EFS)	5.9 months Interval 3.8 to 8.5	—	—	—

SECONDARY outcome

Timeframe: From randomization up to approximately 2.4 years

PFS was defined as time from the date of randomization to the date disease progression due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse) or death from any cause, whichever occurs first. Participants without documented disease progression/relapse or death at the time of the analysis were censored at the date of the last follow-up. Progression-free survival was presented using a Kaplan-Meier estimate.

Outcome measures

Outcome measures
Measure	MDS or CMML: IV Decitabine n=78 Participants Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	MDS or CMML: ASTX727 Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.	AML: IV Decitabine Participants with AML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle=28 days).	AML: ASTX727 Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.
AML: Progression-free Survival (PFS)	6.1 months Interval 4.0 to 8.7	—	—	—

Adverse Events

MDS or CMML: IV Decitabine

Serious events: 24 serious events

Other events: 127 other events

Deaths: 2 deaths

MDS or CMML: ASTX727

Serious events: 81 serious events

Other events: 130 other events

Deaths: 56 deaths

MDS or CMML: Not Treated

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

AML: IV Decitabine

Serious events: 19 serious events

Other events: 70 other events

Deaths: 5 deaths

AML: ASTX727

Serious events: 65 serious events

Other events: 76 other events

Deaths: 61 deaths

AML: Not Treated

Serious events: 1 serious events

Other events: 0 other events

Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure	MDS or CMML: IV Decitabine n=132 participants at risk Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days).	MDS or CMML: ASTX727 n=130 participants at risk Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.	MDS or CMML: Not Treated n=5 participants at risk Participants with MDS or CMML were enrolled in the study but did not receive any study treatment.	AML: IV Decitabine n=78 participants at risk Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2.	AML: ASTX727 n=80 participants at risk Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.	AML: Not Treated n=2 participants at risk Participants with AML were enrolled in the study but did not receive any study treatment.
Blood and lymphatic system disorders Febrile neutropenia	6.1% 8/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	25.4% 33/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	26.2% 21/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Thrombocytopenia	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.3% 3/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Anaemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Leukopenia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Aplasia pure red cell	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Thrombotic thrombocytopenic purpura	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Neutropenia	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Pancytopenia	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Haematotoxicity	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Lymphadenitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Cardiac disorders Myocardial infarction	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Cardiac disorders Acute coronary syndrome	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Cardiac disorders Acute myocardial infarction	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Cardiac disorders Cardiac Failure	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Cardiac disorders Cardiac Failure Congestive	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Cardiac disorders Tachycardia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Colitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Proctitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Diarrhoea	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Enteritis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Gingival bleeding	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Proctalgia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Constipation	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Gastritis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Gastrointestinal Perforation	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Haemorrhoidal Haemorrhage	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Intestinal Ischaemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Pancreatitis Chronic	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Pyrexia	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.3% 3/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Asthenia	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Oedema peripheral	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Multiple Organ Dysfunction Syndrome	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Fatigue	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders General Physical Health Deterioration	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Mucosal Inflammation	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Polyserositis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Sudden Death	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	50.0% 1/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Hepatobiliary disorders Cholelithiasis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Hepatobiliary disorders Hyperbilirubinaemia	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Hepatobiliary disorders Jaundice Cholestatic	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pneumonia	4.5% 6/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	13.1% 17/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	20.0% 16/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Sepsis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Cellulitis	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 5/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Diverticulitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.3% 3/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Influenza	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Upper respiratory tract infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Bacteraemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Bronchopulmonary aspergillosis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Clostridium difficile colitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Colonic abscess	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Device related infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Enterobacter infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Gastroenteritis Escherichia coli	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Gastroenteritis viral	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Oral candidiasis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Parainfluenzae virus infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Peritonsillitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pharyngitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pneumonia cytomegaloviral	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pseudomonal bacteraemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Septic shock	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Sinusitis fungal	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Urinary tract infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Vascular device infection	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 5/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Bronchitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Neutropenic Sepsis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Escherichia Bacteraemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pneumonia Fungal	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Urosepsis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Abdominal Abscess	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Anal Abscess	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Anorectal Infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Cellulitis Staphylococcal	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Cholecystitis Infective	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Clostridium Colitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Corona Virus Infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Enterococcal Bacteraemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Escherichia Urinary Tract Infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Klebsiella Bacteraemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Liver Abscess	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pneumonia Necrotising	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pneumonia Viral	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Post Procedural Infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Sinusitis Aspergillus	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Tuberculosis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Fall	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.3% 3/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Limb injury	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Post procedural haematoma	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Hip fracture	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Ankle Fracture	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Exposure To Communicable Disease	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Multiple Fractures	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Subdural Haematoma	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations Influenza A virus test positive	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations C-Reactive Protein Increased	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Dehydration	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Soft tissue necrosis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma gastric	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Refractory cytopenia with unilineage dysplasia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic Lymphocytic Leukaemia	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Syncope	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.3% 3/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Cerebral haemorrhage	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.5% 2/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Dizziness	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Transient ischaemic attack	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Migraine	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Cerebrovascular Accident	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Epilepsy	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Ischaemic Stroke	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Psychiatric disorders Depression	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Psychiatric disorders Suicide attempt	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Psychiatric disorders Confusional State	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Renal and urinary disorders Acute kidney injury	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Renal and urinary disorders Renal Failure	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.5% 2/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Respiratory Distress	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Angioedema	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Hypersensitivity vasculitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Pyoderma gangrenosum	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Rash	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Embolism	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.3% 3/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Deep vein thrombosis	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Embolism arterial	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Haematoma	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Hypertension	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Hypotension	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.77% 1/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Extravasation Blood	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Phlebitis	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Social circumstances Loss Of Personal Independence In Daily Activities	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.2% 1/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.

Other adverse events

Other adverse events
Measure	MDS or CMML: IV Decitabine n=132 participants at risk Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days).	MDS or CMML: ASTX727 n=130 participants at risk Participants with MDS or CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.	MDS or CMML: Not Treated n=5 participants at risk Participants with MDS or CMML were enrolled in the study but did not receive any study treatment.	AML: IV Decitabine n=78 participants at risk Participants with MDS or CMML received IV infusion of decitabine 20 mg/m\^2, once daily, on Days 1 to 5 in cycles 1 or 2.	AML: ASTX727 n=80 participants at risk Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycles 1 or 2 (each cycle = 28 days). From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.	AML: Not Treated n=2 participants at risk Participants with AML were enrolled in the study but did not receive any study treatment.
Psychiatric disorders Insomnia	2.3% 3/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	14.6% 19/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	11.2% 9/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Thrombocytopenia	39.4% 52/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	69.2% 90/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	38.5% 30/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	58.8% 47/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Neutropenia	34.1% 45/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	60.8% 79/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.3% 8/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	33.8% 27/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Anaemia	35.6% 47/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	55.4% 72/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	26.9% 21/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	51.2% 41/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Leukopenia	17.4% 23/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	28.5% 37/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	11.2% 9/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Lymphopenia	3.8% 5/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 8/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Blood and lymphatic system disorders Febrile Neutropenia	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	8.8% 7/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Eye disorders Conjunctival Haemorrhage	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Constipation	19.7% 26/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	49.2% 64/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.3% 8/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	18.8% 15/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Nausea	17.4% 23/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	48.5% 63/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	21.2% 17/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Diarrhoea	10.6% 14/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	41.5% 54/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	21.2% 17/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Vomiting	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	20.0% 26/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	12.5% 10/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Stomatitis	3.8% 5/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	17.7% 23/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Abdominal Pain	3.8% 5/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	15.4% 20/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Haemorrhoids	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.9% 9/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.5% 6/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Toothache	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.9% 9/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Dyspepsia	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 8/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Fatigue	17.4% 23/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	52.3% 68/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	11.2% 9/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Oedema Peripheral	7.6% 10/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	27.7% 36/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.3% 8/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	20.0% 16/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Asthenia	4.5% 6/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	22.3% 29/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 6/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	25.0% 20/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Pyrexia	7.6% 10/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	20.8% 27/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 6/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	22.5% 18/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Chills	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 13/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Non-Cardiac Chest Pain	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.9% 9/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Pain	3.8% 5/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 8/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
General disorders Peripheral Swelling	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Upper Respiratory Tract Infection	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	12.3% 16/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Urinary Tract Infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	12.3% 16/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 8/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Cellulitis	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	8.5% 11/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.5% 6/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Nasopharyngitis	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Pneumonia	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.5% 6/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Corona Virus Infection	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 5/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Contusion	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	18.5% 24/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Fall	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	12.3% 16/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 8/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Injury, poisoning and procedural complications Procedural Pain	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations Alanine Aminotransferase Increased	5.3% 7/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	15.4% 20/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.5% 6/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations Blood Creatinine Increased	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	13.1% 17/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.5% 6/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations Aspartate Aminotransferase Increased	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.8% 14/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 5/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations Blood Alkaline Phosphatase Increased	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	8.5% 11/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations Blood Bilirubin Increased	2.3% 3/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations Weight Decreased	2.3% 3/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Investigations C-Reactive Protein Increased	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	8.8% 7/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Decreased Appetite	5.3% 7/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	33.1% 43/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.4% 5/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	15.0% 12/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Hypokalaemia	5.3% 7/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	20.8% 27/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	18.8% 15/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Hyperglycaemia	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.8% 14/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Hypocalcaemia	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.8% 14/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Hyponatraemia	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	9.2% 12/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Hypoalbuminaemia	2.3% 3/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.9% 9/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Hypomagnesaemia	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.9% 9/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Metabolism and nutrition disorders Dehydration	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Arthralgia	4.5% 6/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	24.6% 32/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 8/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Back Pain	6.8% 9/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	20.0% 26/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.1% 4/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	11.2% 9/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Myalgia	5.3% 7/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	16.2% 21/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Pain In Extremity	3.8% 5/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	13.8% 18/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Muscle Spasms	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 13/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Bone Pain	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	8.5% 11/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Musculoskeletal Pain	2.3% 3/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 8/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Musculoskeletal and connective tissue disorders Neck Pain	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 8/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Headache	14.4% 19/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	38.5% 50/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.5% 6/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Nervous system disorders Dizziness	9.8% 13/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	32.3% 42/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 8/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Psychiatric disorders Anxiety	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Psychiatric disorders Depression	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Renal and urinary disorders Haematuria	2.3% 3/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Renal and urinary disorders Pollakiuria	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Renal and urinary disorders Acute Kidney Injury	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 5/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	9.1% 12/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	34.6% 45/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Cough	7.6% 10/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	30.8% 40/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	11.2% 9/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain	10.6% 14/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	20.0% 26/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Epistaxis	4.5% 6/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	12.3% 16/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	8.8% 7/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Nasal Congestion	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	11.5% 15/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea Exertional	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Rhinitis Allergic	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	2.3% 3/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Respiratory, thoracic and mediastinal disorders Pleural Effusion	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.5% 6/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Rash Maculo-Papular	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	13.1% 17/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Rash	3.0% 4/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	12.3% 16/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Alopecia	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 13/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Petechiae	3.8% 5/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	9.2% 12/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Pruritus	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.9% 9/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Skin Lesion	0.76% 1/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	6.2% 8/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Skin and subcutaneous tissue disorders Night Sweats	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.4% 7/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Hypotension	4.5% 6/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	12.3% 16/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Hypertension	1.5% 2/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	7.7% 10/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	10.0% 8/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Vascular disorders Haematoma	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	3.8% 3/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	11.2% 9/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Cardiac disorders Atrial Fibrillation	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Dry Mouth	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Gastrointestinal disorders Tongue Ulceration	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	1.3% 1/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Infections and infestations Oral Herpes	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.
Psychiatric disorders Confusional State	0.00% 0/132 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/130 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/5 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	2.6% 2/78 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	5.0% 4/80 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.	0.00% 0/2 • MDS or CMML: From randomization up to 2.7 years; AML: From randomization up to 2.4 years All-cause mortality: Randomized Analysis Set included all randomized participants. Serious adverse events and non-serious adverse events: Safety Analysis Set included all participants who received any amount of study treatment.

Additional Information

Taiho Central

Taiho Oncology, Inc.

Phone: 609-250-7336

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place